• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down2.84% Nasdaq Down2.94%

    Poniard Pharmaceuticals, Inc. (PARD)

    -Other OTC
    0.08 0.00(0.00%) Aug 31, 9:30AM EDT
    |Pre-Market : 2.14 0.00 (0.00%) 4:00PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Poniard Pharmaceuticals, Inc.
    300 Elliott Avenue West
    Suite 530
    Seattle, WA 98119
    United States - Map
    Phone: 206-281-7001
    Fax: 206-284-3181
    Website: http://www.poniard.com

    Index Membership:N/A
    Full Time Employees:7

    Business Summary 

    Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Poniard Pharmaceuticals, Inc.

    Key Executives 
    No officers available for PARD